Caribou Biosciences (CRBU) Change in Receivables (2020 - 2026)
Caribou Biosciences (CRBU) reported Change in Receivables of $158000.0 for Q1 2026, up 189.27% year-over-year from $54621.1 in Q1 2025, and up 191.33% on a QoQ basis from -$173000.0 in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Change in Receivables data on file, last reported at $158000.0 in Q1 2026.
- Quarterly Change in Receivables rose 189.27% year-over-year to $158000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $139000.0 (up 109.89% YoY) and the FY2025 annual result came in at -$196000.0, up 57.21% from the prior year.
- Change in Receivables improved to $158000.0 in Q1 2026 per CRBU's latest filing, from -$173000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.7 million in Q3 2023 and bottomed at -$2.1 million in Q2 2023.
- The 5-year median for Change in Receivables is -$173000.0 (2025), against an average of -$224588.2.
- The widest annual swing landed in 2022, when Change in Receivables slumped 1674.32%; it then surged 517.97% in 2023.
- Tracing CRBU's Change in Receivables over 5 years: stood at -$485000.0 in 2022, then sank by 103.09% to -$985000.0 in 2023, then surged by 114.72% to $145000.0 in 2024, then slumped by 219.31% to -$173000.0 in 2025, then jumped by 191.33% to $158000.0 in 2026.
- Per Business Quant, the three latest CRBU Change in Receivables figures stand at $158000.0 (Q1 2026), -$173000.0 (Q4 2025), and -$152000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | 158,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Dec 31, 2025 | -173,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Mar 31, 2025 | -177,000.00 |
| Mar 31, 2025 | -177,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Sep 30, 2024 | -46,000.00 |
| Jun 30, 2024 | -1.33 Mn |
| Jun 30, 2024 | -1.33 Mn |
| Mar 31, 2024 | 770,000.00 |
| Mar 31, 2024 | 770,000.00 |
| Dec 31, 2023 | -985,000.00 |
| Dec 31, 2023 | -985,000.00 |
| Sep 30, 2023 | 1.65 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | -2.05 Mn |
| Jun 30, 2023 | -2.05 Mn |
| Mar 31, 2023 | 1.33 Mn |
| Mar 31, 2023 | 1.33 Mn |
| Dec 31, 2022 | -485,000.00 |
| Dec 31, 2022 | -485,000.00 |
| Sep 30, 2022 | -395,000.00 |
| Sep 30, 2022 | -395,000.00 |
| Jun 30, 2022 | -1.08 Mn |
| Jun 30, 2022 | -1.08 Mn |
| Mar 31, 2022 | -1.31 Mn |
| Mar 31, 2022 | -1.31 Mn |
| Dec 31, 2021 | 127,000.00 |
| Dec 31, 2021 | 127,000.00 |
| Sep 30, 2021 | 1.82 Mn |
| Sep 30, 2021 | 1.82 Mn |
| Jun 30, 2021 | -74,000.00 |
| Jun 30, 2021 | -74,000.00 |
| Mar 31, 2021 | -74,000.00 |
| Mar 31, 2021 | -74,000.00 |
| Dec 31, 2020 | 150,000.00 |
| Dec 31, 2020 | 150,000.00 |
| Sep 30, 2020 | -21,000.00 |
| Sep 30, 2020 | -21,000.00 |